Search Bar & Filters
Found 7 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating WSD0922-FU in a Phase II, open-label, multicenter study for patients with locally advanced or metastatic non-small cell lung cancer NSCLC whose disease has progressed after first-line treatment with Osimertinib and whose tumors have a C797S mutation in the EGFR gene. This mutation causes resistance to prior treatments, and the study aims to assess safety and effectiveness of this new drug in this specific patient group. WSD0922-FU is an oral drug taken in 21-day cycles, administered twice daily BID at one of two dose levels selected from earlier studies. The drug targets specific EGFR mutations including the resistant C797S mutation. This single-arm study will treat all participants with WSD0922-FU and monitor responses over time. Participants will be closely monitored with assessments every 8 weeks for up to one year to measure tumor response, disease control, progression-free survival, and quality of life using standardized questionnaires. Survival outcomes will be followed for up to 24 months. Safety and side effects will also be recorded throughout the study. The study duration and follow-up are designed to thoroughly evaluate the drugs effects in this advanced NSCLC population.
Actively Recruiting
Researchers are studying younger breast cancer survivors who experience elevated depressive symptoms to compare digital mindfulness meditation programs. This phase III clinical trial evaluates two digital methods a live instructor-led program over Zoom and a self-paced app-based program. The study aims to find which digital approach best improves mental health and well-being after completing primary cancer treatment. Participants are randomly assigned to one of three groups a live online mindfulness group meeting weekly for six weeks via Zoom a self-paced app-based mindfulness program with lessons and exercises unlocked sequentially or a meditation-only control group using guided audio meditations. All participants will have access to the mindfulness meditation app throughout the study, including six months of follow-up. Devices and internet access are provided to those who need them. During the study, participants will attend group sessions or use the app according to their assigned group and complete daily mindfulness practice. Researchers will track engagement and measure depressive symptoms at two weeks, three to six months, and six months after the intervention. They will also assess fatigue and explore factors influencing treatment effects and cost-effectiveness. The total study duration spans the six-week intervention plus six months of follow-up.
Actively Recruiting
Researchers are conducting a pilot Type 1 Hybrid Effectiveness-Implementation Trial to evaluate a tailored lung screening intervention in patients at risk for lung cancer. The study focuses on using an Electronic Health Record-embedded Social Determinants of Health SDoH screening tool in the Emergency Department to identify eligible patients and increase lung cancer screening uptake. The trial aims to assess the reach and preliminary effectiveness of this intervention in comparison with enhanced usual care by examining factors such as health literacy, mistrust, stigma, fatalism, knowledge, and lung screening health beliefs. The study compares two groups one receiving LungTalk, a tailored, interactive educational program delivered via iPad that adapts content based on smoking status and perceived barriers and another receiving a non-tailored lung screening pamphlet emailed to patients along with patient navigation support. LungTalk includes audio, video, and animation to engage participants, while the pamphlet provides standard educational information about lung cancer risk and screening. Participants are identified through SDoH screening and receive tailored or standard educational materials accordingly. Participants aged 50 to 80 who currently smoke or quit within 15 years and have a 20 pack-year smoking history are involved. Researchers will measure lung cancer screening uptake and stage of adoption at 1 week, 1 month, and 6 months post-intervention. Additional assessments include health literacy, medical mistrust, stigma, perceived risk, benefits and barriers to screening, self-efficacy, knowledge, and fatalism at 1 week and 1 month. The study uses randomized methods and collects data from electronic health records to monitor outcomes and reach over the trial period.
Actively Recruiting
Researchers are studying whether Tamsulosin can reduce the high rate of postoperative urinary retention POUR in older men undergoing thoracic cancer surgery. POUR is common, especially in older men with enlarged prostates, and can lead to infections, discomfort, longer hospital stays, and other complications. This early phase study aims to determine if taking Tamsulosin before surgery lowers the incidence of POUR and helps patients regain normal urinary function sooner. Participants will take Tamsulosin 0.4 mg daily for seven days before their planned thoracic oncological surgery. They will also record their medication use in a diary. On the day of surgery, they will take Tamsulosin with a sip of water. After surgery, bladder ultrasounds will measure urine volume and retention to assess POUR. Standard bladder care will be provided if spontaneous urination does not occur or if urine residual is high, following a specific management plan. During the study, researchers will monitor spontaneous urination within 6 to 8 hours after surgery, the time and volume of urination within 24 hours, and the amount of urine left in the bladder. They will also track how many participants need medical intervention due to inability to urinate. Monitoring will help assess Tamsulosins potential to prevent urinary retention after surgery. The study is expected to be completed by June 2027.
Actively Recruiting
Researchers are studying targeted genomic analysis of blood and tissue samples from patients with cancer, focusing on rare cancers with poor prognosis or limited treatment options. This observational research aims to identify genetic changes using genomic sequencing to help understand cancer development and to provide clinicians with mutation data that may guide treatment or referral to relevant studies. The study also collects clinical outcomes and tumor genome data for future analysis and cancer model development. The study involves analyzing previously collected tumor tissue samples using next-generation sequencing to detect mutations. Patients may also provide blood samples for analysis of circulating cell-free DNA and circulating tumor cells. These procedures support the identification of actionable mutations that may have available targeted therapies. The research includes correlative laboratory biomarker analysis. Participants are followed after study completion every 3 months for 2 years, then every 6 months for up to 15 years to monitor clinical outcomes and mutation frequencies. Researchers measure the frequency of specific mutations and the rate of actionable mutations in rare or poor prognosis cancers over this period. This long-term follow-up helps correlate genomic findings with patient outcomes and supports future research developments.
Actively Recruiting
Researchers are evaluating the effect of atezolizumab, alone or combined with recombinant human hyaluronidase, compared to standard observation in preventing the return of stage I non-small cell lung cancer NSCLC after complete surgical removal. This phase III trial focuses on patients who have undergone surgical resection and aims to see if these immunotherapies may better prevent cancer recurrence than usual monitoring. Atezolizumab is a monoclonal antibody that may help the immune system attack cancer cells, and the combination with hyaluronidase may improve drug absorption. Participants are randomly assigned to one of two groups. One group undergoes observation with regular CT scans and optional blood sample collection for one year. The other group receives atezolizumab intravenously or atezolizumab with hyaluronidase subcutaneously every three weeks for up to one year 17 cycles, alongside similar monitoring. After treatment, patients are followed up at 30 days atezolizumab group only, then every 6 months for 3 years, and annually for an additional 7 years, totaling 10 years of follow-up. During the study, participants will have regular CT scans and may provide blood samples to help assess their health and disease status. Researchers will monitor disease-free survival, overall survival, recurrence rates, and adverse events over up to 10 years. Safety and treatment effects will be closely observed throughout treatment and follow-up to understand long-term outcomes and potential benefits of the therapies compared to observation alone.
Actively Recruiting
Researchers are evaluating how measuring circulating tumor DNA ctDNA in blood may help identify patients with urothelial cancer who need additional immunotherapy after surgical removal of the bladder, kidney, ureter, or urethra. This phase IIIII trial studies whether treatments with immunotherapy drugs nivolumab and relatlimab can improve survival and prevent cancer from returning in these patients. Participants are assigned to one of two groups based on their ctDNA test results after surgery. Those with detectable ctDNA receive either nivolumab alone or nivolumab combined with relatlimab intravenously every 28 days for up to 12 cycles. Participants without detectable ctDNA are randomized to receive nivolumab immediately or to undergo ctDNA surveillance and start nivolumab only if ctDNA becomes detectable. Throughout the study, patients undergo tissue and blood collections, imaging scans like CT or MRI, and may have cystoscopy. During the trial, participants are monitored with blood tests, tissue sampling, imaging, and questionnaires to assess cancer recurrence, survival, and quality of life. Researchers measure outcomes such as ctDNA clearance, overall survival, and disease-free survival over up to 5 years after treatment. Safety and side effects are also tracked. Follow-up visits occur regularly after treatment completion to continue monitoring health and disease status.